Literature DB >> 6547068

The effects of timolol on arrhythmias and prostanoid release during canine myocardial ischaemia and reperfusion.

S J Coker, J R Parratt.   

Abstract

Timolol (50 micrograms kg-1), administered intravenously to chloralose-anaesthetized open-chest greyhounds 30 min prior to occlusion of the left anterior descending coronary artery, reduced heart rate and mean arterial blood pressure. This dose caused a 20 fold increase in the dose of isoprenaline required to increase heart rate by 25 beats min-1. During the first 30 min of myocardial ischaemia the number of extrasystoles in the timolol-treated dogs (327 +/- 179) was less than in the control group (888 +/- 168) and none of the dogs that received timolol fibrillated. The haemodynamic changes induced by coronary artery occlusion (decreased cardiac output and stroke volume, increased peripheral vascular resistance) were similar in both control and timolol-treated dogs as were the increases in PCO2 and decreases in PO2 and pH in blood draining from the ischaemic myocardium. Timolol did not alter the release during myocardial ischaemia, of either thromboxane B2 or prostacyclin (measured as 6-keto PGF1 alpha). Reperfusion-induced ventricular fibrillation occurred in 7 out of 8 control dogs and in 5 out of 10 timolol-treated dogs. The overall survival following occlusion and reperfusion was improved by 10% to 50% by timolol.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6547068      PMCID: PMC1986916          DOI: 10.1111/j.1476-5381.1984.tb16134.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  11 in total

1.  A comparison of methods for the measurement of cardiac output and blood oxygen content.

Authors:  I R Douglas; J A MacDonald; G F Milligan; A Mellon; I M Ledingham
Journal:  Br J Anaesth       Date:  1975-04       Impact factor: 9.166

2.  Differing mechanisms for ventricular vulnerability during coronary artery occlusion and release.

Authors:  R Corbalan; R L Verrier; B Lown
Journal:  Am Heart J       Date:  1976-08       Impact factor: 4.749

3.  Comparison of a new beta adrenergic blocker (MK 950) and propranolol in man.

Authors:  M Ulrych; J Franciosa; J Conway
Journal:  Clin Pharmacol Ther       Date:  1972 Mar-Apr       Impact factor: 6.875

4.  Changes in blood flow and oxygen consumption in normal and ischaemic regions of the myocardium following acute coronary artery ligation.

Authors:  R J Marshall; J R Parratt; I M Ledingham
Journal:  Cardiovasc Res       Date:  1974-03       Impact factor: 10.787

5.  Thromboxane and prostacyclin release from ischaemic myocardium in relation to arrhythmias.

Authors:  S J Coker; J R Parratt; I M Ledingham; I J Zeitlin
Journal:  Nature       Date:  1981-05-28       Impact factor: 49.962

6.  Effects of short-term beta blockade on blood pressure, plasma thromboxane B2, and plasma and urinary prostaglandins E2 and F2 alpha in normal subjects.

Authors:  R M Graham; W B Campbell; E K Jackson
Journal:  Clin Pharmacol Ther       Date:  1982-03       Impact factor: 6.875

7.  Nifedipine reduces arrhythmias but does not alter prostanoid release during coronary artery occlusion and reperfusion in anaesthetised greyhounds.

Authors:  S J Coker; J R Parratt
Journal:  J Cardiovasc Pharmacol       Date:  1983 May-Jun       Impact factor: 3.105

8.  Radioimmunoassay techniques for the determination of the local release of prostaglandins and thromboxanes.

Authors:  S J Coker; B Clarke; I J Zeitlin
Journal:  J Pharmacol Methods       Date:  1982-05

9.  Reperfusion ventricular tachyarrhythmias: correlation with antecedent coronary artery occlusion tachyarrhythmias and duration of myocardial ischemia.

Authors:  C W Balke; E Kaplinsky; E L Michelson; M Naito; L S Dreifus
Journal:  Am Heart J       Date:  1981-04       Impact factor: 4.749

10.  Effect of timolol on platelet aggregation in coronary heart disease.

Authors:  E Thaulow; J Kjekshus; J Erikssen
Journal:  Acta Med Scand Suppl       Date:  1981
View more
  1 in total

1.  Indomethacin does not attenuate the ocular hypotensive effect of timolol.

Authors:  Q A Mekki; S M Abrams; A D Petounis; P Turner
Journal:  Br J Clin Pharmacol       Date:  1985-04       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.